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Abstract  
Background and Aims: Viral hepatitis is a global health problem with a high mortality rate. 
Recently, a new Flavi-like virus, provisionally named hepatitis G virus (HGV), has been 
described. HGV does not induce an immune response that is consistently detectable by using 
recombinant proteins from prokaryotic expression, therefore studies have been conducted by 
using polymerase chain reaction (PCR) based system. HGV is a blood born virus that is 
parenterally transmitted, however incidence of severe hepatitis with HGV is rare, and most 
infections are subclinical or mild.  
Methods: A total of 180 blood specimens from chronic hepatitis patients (80 were HBV and 
HCV positive and 100 were Non B-Non C hepatitis patients) were collected, plasma was 
separated and stored at -80° C. The specimens were examined by the method of RT-PCR. 
Results: There were 36 male and 14 female patients, majorities (95%) were living in the city 
of Kerman, and average age was 35 years old. The rate of infection with hepatitis viruses 
were as follows: chronic liver disease, including 21 (52.5%) with chronic hepatitis B 
infection, 17 with chronic hepatitis C infection (42.5%) co-infected with HGV, respectively 
(p = 0.03). Of the 180 patients, 40 were HGV RNA positive (17.7%). 
Conclusion: HGV co-infection is highly prevalent among Kerman blood donors who are 
infected with HBV or HCV. The results also reveal that population negative for HCV and 
HBV are a low risk group for HGV infection. 
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Introduction 
 
 
epatic cirrhosis is an important public 
health problem; the major burden is 
caused by infection with primary 
hepatotropic viruses, Hepatitis B virus (HBV), 
hepatitis C virus (HCV) and hepatitis D virus 
(HDV). Many individuals who have clinical 
evidence of virus-induced chronic liver disease 
fall in the non-B, non-C category, suggesting 
the existence of one or more yet unidentified 
additional viral agent(s). HGV, a novel human 
Flavivirus is considered to be a putative 
hepatotropic agent. This virus is widely 
distributed throughout the world and its 
presence has been reported from different 
geographical areas (1). GB virus-C/hepatitis G 
virus (GBV-C/HGV) is an enveloped positive-
stranded RNA virus with a genome of about 
H
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9.4 kb, belonging to the Flaviviridae. It is 
distributed worldwide, and at least five major 
genotypes of this virus have been proposed 
based on the sequence analysis of the 5´ GBV- 
noncoding region 5´ (NCR) or E2 gene. HGV 
is transmitted through blood transfusion. A few 
cases of fulminant hepatitis due to HGV 
infection have been reported, but it remains 
unclear whether the hepatitis was actually 
caused by HGV (2). HGV does not induce an 
immune response that is consistently detectable 
by using recombinant proteins from 
prokaryotic expression; hence prevalence 
studies have been conducted by using 
polymerase chain reaction (PCR) based 
system. HGV-RNA has been detected in many 
human populations(3).Despite the availability 
of diagnostic tests for detection of  hepatitis C 
virus (HCV) and hepatitis E virus (HEV),  
cases of acute and chronic hepatitis in which 
patients do not exhibit markers for any known 
hepatitis viruses still exist and are referred to 
as non-A–E hepatitis. A total of 4%–20% of 
acute hepatitis cases in Europe and the United 
States are associated with non-A–E hepatitis 
although the polymerase chain reaction (PCR) 
has significantly enhanced the ability to detect 
viral infections, 40% of fulminant hepatitis 
cases are of unknown etiology (4). Hepatitis A, 
B, C, D and E are well characterized with an 
unequivocal association with liver disease in 
human beings. However the role of HGV in 
hepatitis is controversial (4,5). The genome of 
HGV contains a 458 nucleotide long 5’ non-
coding region (NCR), a single open reading 
frame (ORF) encoding a polyprotein of  about 
2900 amino acids, and a 3’ NCR of 315 
nucleotides(6) . The detection of viral genome 
is carried out by RT-PCR for diagnosis of 
infection. We have attempted to determine the 
prevalence rate of HGV infection among 
healthy blood donors and blood donors with 
HBV or HCV infection in Kerman province, 
Southeast of Iran. HGV capsid  protein  is  
absent  or  defective  and  the  capsid  may  be  
provided  by  another  virus (12). Therefore, 
co- infection  of  HGV  with  other viruses  is  
an  interesting  and  important  subject  for 
investigation . The  reported  HGV  infection 
rates  in  hepatitis  C  patients  were  
approximately 20% (13,14) , but  a  quite  
lower  co infection  rate  of  HGV and  HCV  
(5.6%)  was  also  reported (12) . HGV RNA 
can be found in serum for 2-20 weeks after 
infection. Retrospective studies of stored sera 
show that HGV can cause a persistent infection 
up to7 to 16 years (15). 
 
Methods  
 
Patients  
A total of 80 consecutive patients with biopsy 
proven chronic hepatitis, who visited the out 
Patient Clinic of Afzalipoor Hospital, Kerman 
(southeast of Iran) between April 2006 and 
May 2007, were included in the study. Patients 
were diagnosed as having chronic hepatitis, 
using conventional clinical, biochemical and 
histological criteria and PCR for HBV and 
HCV. The mean duration of the disease was 10 
± 6 months. Anti-HCV or HBsAg positive 
patients with persistently elevated alanine 
amino transferase (ALT) levels (>50 IU/l), 
detectable HCV RNA or HBV DNA in serum, 
and a liver biopsy that indicates either portal or 
bridging fibrosis or at least moderate degree of 
inflammation and necrosis were included under 
HCV or HBV related chronic hepatitis 
categories. Patients with autoimmune liver 
disease, drug-induced hepatitis and alcoholic 
liver injury were excluded. A group of 100 
patients (chronic non-B, non-C hepatitis) were 
seronegative for both HBV and HCV markers 
as revealed by ELISA and PCR studies. 
History of blood transfusion (HBT) was 
recorded in 6 patients in this group. Another 
group of 40 patients (chronic hepatitis B) was 
 Contradictory data about the clinical 
importance  of  HGV infection  and  nucleotide 
sequence  mutation  of the viral isolates 
indicated that the pathogenesis and   variability 
of  the virus are not fully understood(16).  In 
this  study,  HGV  RNA  in  the  180  samples 
were detected by  RT-  PCR with  two different 
sets  of  primers. The results of  this  study 
may contribute  to the determination of   HGV 
co infection frequency  in  HCV and HBV
patients, choice of the methods with high 
sensitivity and the primers with high 
efficiency for HGV RNA detection (4).  
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seropositive for HBsAg and HBV DNA and 
seronegative for anti-HCV and HCV RNA. 
Twelve patients had HBT in this group. A total 
of 40 patients (chronic hepatitis C) were 
seropositive for anti-HCV and HCV RNA and 
seronegative for HBsAg and HBV DNA. 
Fourteen patients in this group had HBV. The 
healthy controls (n=100) were drawn from 
healthy men and women voluntary blood 
donors with normal liver function test (LFT) 
profiles and were serologically negative for 
HBV and HCV. Twenty five individuals had 
HBT in this group. 
Serology 
Serum samples collected from all 100 chronic 
hepatitis patients and 100 healthy control 
subjects were included for serological tests for 
hepatitis B and C viruses. Enzyme Link 
immuno sorbent assay (ELSIA) for HBsAg 
was carried out by using commercial ELISA 
kit (RADIM, Italy). Third generation ELISA 
kits was used for detection of antibody to HCV 
(RADIM, Italy). The analysis was based on the 
200 patients using SPSS 11.5 for Windows 
software (SPSS Inc. Chicago, Illinois, and 
USA). Prevalence rate and 95% confidence 
intervals (95% CI) were calculated. 
Molecular test 
Five ml of blood sample was collected from 
each patient in a sterile container with 100 µl 
EDTA 0.5 M and mixed. Plasma was separated 
and stored at –80°C till further testing.  Plasma 
samples of HCV or HBV patients were 
obtained from the Afzalipoor hospital in 
Kerman, Iran. The 80 samples were confirmed 
to be HCV or HBV positive by PCR and RT-
PCR Method (HBV &HCV RG kit, Qiagen, 
Germany). This test is a routine work in our 
laboratory for detection of HCV and HBV. 
Forty samples were HCV Positive and 40 
samples were HBV positive, and four samples 
were both HCV and HBV Positive. 
Viral RNA was extracted from 200µl plasma 
by using High pure viral nucleic acid kit 
(Roche, Germany) and resuspended in 50µl 
elution buffer, RNA stored at –80°C for further 
testing.  
RT-PCR for HGV 
All samples were tested for the presence of 
HGV RNA by Nested RT-PCR method. cDNA 
synthesis was subjected to PCR using specific 
primers for the 5'-UTR genome regions in all 
samples and this region is highly conserved in 
the HGV. Reverse transcription was performed 
at 42°C for 60 minutes in 20 ml reaction 
volume using avian myeloblastosis virus 
reverse transcriptase(AMV) (Bioneer, Korea) 
and external antisense primer (for the detection 
of genomic RNA), using a thermal cycler 
(MWG, Germany). Five µl of  cDNA was 
added to 25 µl of reaction mixture containing 5 
units Taq polymerase, 0.01% gelatin,0.6 µM of 
each primer, 200 µM of each deoxynucleotid 
triphosphate, 5 µl of reaction buffer (50 mM 
KC1, 10 mM tris-HCI, pH = 8.3) and 1.5 mM 
MgCl2. 
Polymerase chain reaction was performed for 
forty cycles at 94° C for 60 s, 55° C for 70s 
and at 72° C for 1.5 min. The condition for the 
second amplification step was similar to the 
first one, 20 µl PCR reaction containing 1 µl of 
first step PCR product. For primers the inner 
was sense located at position 134, and anti 
sense primer located at position 467 were used.  
Samples containing 333 bp PCR products in 
agarose gel were considered as HGV RNA 
positive, stained with ethidium bromide, and 
visualized under UV light. Standard 
precautions were taken to avoid sample-to-
sample contamination and PCR product carry-
over (17). 
In each step of PCR, sterile water, normal 
serum control and a negative serum (non 
reactive  on multiple assays) were used as 
negative controls, and a positive UTR region 
of HGV  cloned plasmid (kindly provided by 
Dr M N Al-Ahdal) was used as positive 
control. 
 
Results 
 
There were 36male and 14 female patients, 
majority (95%) were from Kerman, average 
age was 35 years old. The rest have chronic 
liver disease, including 21 (52.5%) with 
chronic hepatitis B infection, 17 with chronic 
hepatitis C infection (42.5%) both were co-
infected with HGV, respectively (p = 0.03).Of 
the 180 patients, 40 were HGV RNA positive 
(17.7%). Among the chronic hepatitis B 
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patients, alanine transferases (ALT) were 
between 52 and 79 U/l in the HGV RNA-
positive and HGV negative patient groups, 
respectively (p = 0.4). Half of those (21/40)  
with positive marker of hepatitis G infection 
(HGV RNA) were cirrhotic, Whereas only 9.5 
% of  those without positive marker of 
hepatitis G infection were cirrhotic (N.S.). 
Similarly, among the patients with chronic 
hepatitis C, the mean ALT was 48 and 94 U/l 
in the HGV. 
RNA-positive and HGV-negative patient 
groups, respectively (p= 0.05). Forty-two 
percent (17/40) of these patients with positive 
marker of hepatitis G infection were cirrhotic; 
in contrast to 15.6% of those without cirrhosis 
(N.S.).Twelve of the chronic hepatitis patients 
had background of end-stage renal disease.  
Among the 100 samples which were positive 
for HBV or HCV, a couple of the samples 
were positive for all three viral markers (HBV, 
HCV, and HGV), and among 100 samples 
which were healthy blood donor (general 
population), only 2 of the samples were 
positive for HGV RNA. Age and sex 
distribution of HGV RNA, HBV and HCV 
positivity are shown in Table 3. There was 
male predominance and majority of cases 
belonged to age group of 20-39 years. 
 
There were no differences in age or sex 
between the HGV-positive and HGV-negative 
groups both for HCV and HBV infected 
patients. Overall the main risk factor for 
infection with hepatitis virus reported for all 
groups was a hospital stay with or without 
surgery, while a history of transfusion was 
reported by a minority of patients. The 
relationship between disease severity and the 
presence of HGV RNA in serum is presented 
in Table 2. No significant differences were 
found between the mean alanine 
aminotransferase levels in HGV infected and 
uninfected subjects .When histological disease 
severity was assessed, no significant 
differences were present in total HAI score, 
fibrosis interlobular necrosis, portal 
inflammation or degree of piecemeal necrosis 
(Table 4). The prevalence of HBeAg and anti-
HBe was not statistically different in HGV-
positive and HGV-negative chronic hepatitis B 
patients.    
 
Discussion 
 
Prevalence of HGV in healthy blood donors 
around the world is variable. The lowest 
prevalence rate was reported in one study from  
location Sequence position Name 
108- 123 agg tgg atg ggt gat    Sence  G1 
    5 31- 510 tgc cac ccg ccc tca ccc gaa Antisense G2 
134 – 155 tgg tag gtc gta aat ccc ggt Sence  G3 
467 – 445   ggr gct ggg tgg ccy cat gcw t Antisense G4 
Subject n HGV (%) 
General population* 
 
100 2(2) 
Type-B hepatitis patients 40 21(52.5) 
Type-C hepatitis patients 40 17(42.5) 
Total 180 40(17.7) 
Table 2: The prevalence of HGV infection in patients from Kerman, Iran. 
Table 1: Primer sequences for PCR and RT-PCR 
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China (0.7%) compared to 5.7% in Vietnam. 
Overall, the prevalence of HGV-RNA among 
blood donors ranged from 1% to2% in most  
countries. However, the HCV and HCV-RNA 
positive blood donors have the highest 
prevalence rate of HCV-RNA. In patients with 
acute nonA-E hepatitis, the prevalence of HGV 
ranged from 2-14.6%, a range similar to that 
found among patients with chronic non-A-E 
hepatitis (4-17.9%). However, among patients 
with acute A, B or C hepatitis, the prevalence 
rate of HGV-RNA virus ranged from 9.5-41%. 
In patients with chronic HBV the prevalence of 
HGV-RNA ranged from 3.2-9.8% compared to 
8.2-21% in patients with chronic HCV 
hepatitis. In patients with fulminant non-A-E 
hepatitis, only one study reported HGV-RNA. 
However rate of HGV infection in patients 
with hepatocellular carcinoma was about 6% 
and in patients with alcoholic or autoimmune 
hepatitis was close to 10% (4). 
In this study a total of 180 patients with 
chronic hepatitis were tested for HGV RNA by 
RT-PCR. All the samples were also tested for 
 
Total 
 
40-49 
M         F 
Age group 
30-39 
M        F 
 
 
20-29 
M       F 
 
Viral Markers 
Positive /total 
21/40 1/2      0/1 6/13           3/7 8/12        3/5 
Type-B hepatitis 
patients 
 
17/40 2/4       1/3 5/12          1/5 2/6    6/10 Type-C hepatitis patients 
2/100 2/8       0/4 0/48          0/15 0/18        0/7 General population  
40/180 4/14     2/8 14/73       5/27 18/40    7/18 Total 
Type C hepatitis(40) Type B Hepatitis(40)    
HGV Neg(23) HGV 
Pos(17)  
HGV 
Neg(19)  
HGV Pos (21)  
37±6.6 28±4.3 32±7.5 35±6.5  Mean 
Age±SD  
46±18 71±23 55±13 65±14  Mean 
ALT±SD  
2.4±0.2 2.5±0.7 2±0.6 1.5±1  Fibrosis 
Score±SD  
2.9±2 3±2.1 1.9±3 1.6±2.5  Piecemeal 
necrosis’s  
2.4±1.1 2.3±0.9 2.1±1.2 2.5±1.2  Intralobular 
Necrosis±SD  
3.6±0.2 3.4±0.3 3.1±0.2 3±0.3  Portal 
inflammation 
±SD  
18(78)  10(58) ---------   ----  HBe-Ag 
Positive 
Table 3: Age and Sex wise distribution of patients for HGV positive. 
Table 4: Clinical and histopathological characteristics of 80 patients with hepatitis B and C 
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HBsAg and antibody to HCV. Fifty out of 180 
(27.7%) were positive for HGV RNA. The 
result was confirmed twice by PCR. The 
prevalence rate of HGV infection observed 
was 27.7% in our study. In other countries 
prevalence rates range from 1- 14% (19,20). In 
a group of about 300 West Africans, 14% 
prevalence rate of HGV RNA was noted (21). 
Adhani et al, had found 1-2% positivity in 
blood donors in U.S.A (22). In a Korean study, 
HGV was detected in 1-2.5% of blood donors 
(23). In Western India Arankalle et al reported 
no positivity of HGV RNA in 51 voluntary 
blood donors (24). Whereas Jain et al in a 
study in Northern India found 24% of blood 
donors were positive for HGV RNA (25).The 
prevalence of 27.7% probably represents true 
prevalence rate of HGV infection our country. 
Though higher prevalence rate were observed 
among males and in age group of 20-39 years, 
the finding was not statistically significant. Co-
infection of HGV with HBV and HCV 
suggests similar modes of transmission. HGV 
has been isolated in semen of spouses of 
infected persons (26). 
Out of 40 donors positive for HBsAg, 21 were 
also positive for HGV RNA showing a co-
infection of 52.5%. Similarly, out of 40 donors 
positive for antibody to HCV, 17 were positive 
for HGV RNA showing a co-infection rate of 
42.5%. As both HBV and HCV are transmitted 
parenterally and by sexual route, it suggests 
that HGV also follows a similar transmission 
route. The co-infection rate of HGV with HCV 
is 42.5% depending on risk factors and with 
HBV is 52.5% .Prevalence of HGV RNA in 
healthy blood donors were 12% .In our study 
the prevalence of HGV infection did not show 
any  significant difference among blood donors 
positive for HBsAg and with antibody to HCV. 
The co-infection rate is comparable to other 
studies mentioned.  
In the absence of any reliable serological assay 
for the diagnosis of infection, HGV RNA 
detection by RT-PCR remains the only 
available diagnostic tool indicating an ongoing 
infection (27). 
So far there is no conclusive evidence that 
HGV produces hepatitis. However presence of 
HGV in hepatitis cases casts a doubt on this 
finding .Although the disease activity of HGV 
is not yet fully elucidated viral RNA is 
detected more frequently in patients with liver 
disease than in control subjects. Conducting 
prevalence rate studies in blood donors may be 
helpful in future when the exact role of HGV 
in inducing hepatitis is known. 
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